Patents Assigned to Universite de Strasbourg
-
Publication number: 20210246254Abstract: A rigid foam or composition allowing a rigid foam to be obtained made from polyurethane and/or polyisocyanurate. The rigid foam or composition includes polyols selected from polyester polyols and polyether polyols; the polyols include: 5 to 50% of a polyester polyol A by weight relative to the total weight of the polyols; and a polyol B selected from polyester polyols B and polyether polyols B. The polyester polyol A is of general formula Rx-Ry-Z-Ry?-Rx? in which Z is a C3 to C8 alcohol sugar chosen from glycerol, sorbitol, erythritol, xylitol, araditol, ribitol, dulcitol, mannitol and volemitol. Ry and Ry? are diesters of formula —OOC—Cn-COO— in which n is between 2 and 34, and Rx and Rx? are identical or different C2 to C12 monoalcohols.Type: ApplicationFiled: January 22, 2019Publication date: August 12, 2021Applicants: TEREOS STARCH & SWEETENERS BELGIUM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SOPREMA, UNIVERSITÉ DE STRASBOURGInventors: Pierre Etienne BINDSCHENDLER, Alexandru SARBU, Rémi PERRIN, Pierre FURTWENGLER, Luc AVÉROUS, Andréas REDL
-
Publication number: 20210221784Abstract: The invention relates to compounds, pyridine derivatives, and pharmaceutical 10 compositions containing same for use in the treatment of pain. It also relates to specific compounds, compositions comprising the same and uses thereof, in particular in the treatment of pain.Type: ApplicationFiled: February 5, 2019Publication date: July 22, 2021Applicants: Université de Strasbourg, Centre National de la Recherche ScientifiqueInventors: Martine SCHMITT, Jacques BRICARD, Frédéric SIMONIN, Jean-Jacques BOURGUIGNON, Frédéric BIHEL, Khadija ELHABAZI
-
Patent number: 11046657Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.Type: GrantFiled: July 13, 2017Date of Patent: June 29, 2021Assignees: Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Universite Paris-Sud, Centre International de Recherche aux Frontieres de la ChimieInventors: Dominique Bonnet, Nelly Frossard, Jean-Luc Galzi, Christophe Guignabert, Marcel Hibert, Frédéric Simonin, Sylviane Muller
-
Patent number: 11040113Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.Type: GrantFiled: March 22, 2016Date of Patent: June 22, 2021Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Université de StrasbourgInventors: Hélène Puccio, Françoise Piguet
-
Publication number: 20210130875Abstract: The present invention concerns an oligonucleotide-functionalized hydrophobic polymer nanoparticle and method of its preparation. Said nanoparticle is a dye-loaded polymeric nanoparticle, and being functionalized by: (a) target-specific oligonucleotides, and/or (b) non-specific oligonucleotides.Type: ApplicationFiled: March 8, 2019Publication date: May 6, 2021Applicants: Universite de Strasbourg, Centre National de la Recherche ScientifiqueInventors: Andrii KLYMCHENKO, Nina MELNYCHUK, Andréas REISCH
-
Patent number: 10988737Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.Type: GrantFiled: April 28, 2016Date of Patent: April 27, 2021Assignees: Universite de Strasbourg, Institut National de la Sante et de la Recherche Medicale Institut, Hospitalier Universitaire de Strasbourg, ICAHN School of Medicine at Mount SinaiInventors: Thomas Baumert, Yujin Hoshida
-
Patent number: 10983271Abstract: Some embodiments are directed to optical conductors comprising one or more fibrillar organic supramolecular species including an association of triarylamines, methods of preparation and applications thereof as optical and plasmonic waveguides.Type: GrantFiled: January 27, 2017Date of Patent: April 20, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE STRASBOURGInventors: Nicolas Giuseppone, Joseph John Armao, IV, Gero Decher
-
Publication number: 20210094966Abstract: A process for producing a five-membered polycycloaliphatic carbonate including a step of reacting a suspension of a powdered sugar alcohol within a carbon dioxide source and a catalyst compound which is soluble in the carbon dioxide source at the reactional temperature. The invention also concerns a process for producing non-isocyanate polyurethane and/or a polycarbonate and/or polyethers including the step of obtaining a five-membered polycycloaliphatic carbonate according to the process for producing a five-membered polycycloaliphatic carbonate.Type: ApplicationFiled: March 30, 2018Publication date: April 1, 2021Applicants: TEREOS STARCH & SWEETENERS BELGIUM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SOPREMA, UNIVERSITÉ DE STRASBOURGInventors: Pierre-Étienne BINDSCHEDLER, Rémi PERRIN, Pierre FURTWENGLER, Luc AVÉROUS, Andreas REDL
-
Patent number: 10946305Abstract: The invention relates to a method for producing a cocrystal of at least two compounds by means of instantaneous evaporation or flash evaporation, for example for the production of cocrystals in the fields of energetic materials, pharmaceutical compounds, phytopharmaceutical compounds, ferroelectric materials, non-linear response materials or bioelectronic materials.Type: GrantFiled: July 6, 2015Date of Patent: March 16, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE DE STRASBOURG, ISL-INSTITUT FRANCO-ALLEMAND DE RECHERCHES DE SAINT-LOUISInventors: Benedikt Risse, Denis Spitzer, Florent Pessina
-
Patent number: 10927371Abstract: The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands.Type: GrantFiled: January 30, 2009Date of Patent: February 23, 2021Assignees: Centre National De La Recherche Scientifique (CNRS), Universite De Strasbourg, Pollyplus TransfectionInventors: France Jean-Paul Behr, Mitsuharu Kotera, Nadege Pfender, Jean-Serge Remy
-
Patent number: 10927170Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.Type: GrantFiled: May 15, 2018Date of Patent: February 23, 2021Assignees: Universite de Strasbourg, Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche MedicaleInventors: Thomas Baumert, Eric Robinet, Mirjam Zeisel
-
Publication number: 20210040204Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: ApplicationFiled: October 27, 2020Publication date: February 11, 2021Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 10912568Abstract: The balloon includes a pouch formed of a sealed wall delimiting an internal space, and a valve for filling the internal space with a fluid, capable of being occluded after filling the internal space. The pouch delimits a fluid-draining orifice opening into the internal space. The balloon further includes an occluding ball that occludes the draining orifice. The occluding ball can be spherical or polyhedral, and be capable of releasing the draining orifice under the effect of a magnetic field, so as to enable the at least partial drainage of the fluid contained in the internal space. The occluding ball is movable along at least two distinct axes in relation to the pouch.Type: GrantFiled: April 28, 2017Date of Patent: February 9, 2021Assignees: UNIVERSITÉ DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HÔPITAUX UNIVERSITAIRES DE STRASBOURG (HUS), INSTITUT HOSPITALO-UNIVERSITAIRE DE STRASBOURG, INSTITUT DE RECHERCHE CONTRE LES CANCERS DE L'APPAREIL DIGESTIF, BS MEDICAL TECH INDUSTRYInventors: Nicolas Sananes, Romain Favre, Joël Leroy, Christian Debry, Christian Goetz, Bruno Mutet, Juan Hernandez, Bertrand Basch, Raymond Basch
-
Patent number: 10879860Abstract: A magnetic operational amplifier having a differential stage includes a first magnetic field effect transistor MAGFET and a differential signal conditioner, the differential signal conditioner including a load stage, a differential input pair connected to the load stage and a biasing current source connected to the differential input pair; the magnetic field effect transistor MAGFET being connected to the load stage as a second differential input pair and the differential signal conditioner including a second biasing current source connected to the magnetic field effect transistor MAGFET.Type: GrantFiled: April 28, 2017Date of Patent: December 29, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE STRASBOURGInventors: Vincent Frick, Laurent Osberger
-
Patent number: 10864296Abstract: A polyelectrolyte coating comprises at least one polycationic layer consisting of at least one polyarginine as herein defined and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit. Also disclosed is a method of preventing a bacterial infection in an individual.Type: GrantFiled: July 11, 2017Date of Patent: December 15, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE STRASBOURG, PROTIP MEDICALInventors: Philippe Lavalle, Pierre Schaaf, Nihal Engin Vrana, Angela Mutschler
-
Patent number: 10865435Abstract: Embodiments of the present disclosure relate to methods of screening and optionally designing compounds as inhibitors of Mfd (Mutation Frequency Decline), such compounds being useful for the treatment of bacterial infections. Embodiments of the methods include culturing pathogenic bacteria expressing functional Mfd with various concentrations of 1 mM or less, incubating the cultures with and without nitric oxide stress conditions, evaluating bacterial survival in each of the cultures, and calculating the concentration of the molecule required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the untreated cultures and cultures following nitric oxide stress.Type: GrantFiled: May 3, 2017Date of Patent: December 15, 2020Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURGInventors: Nalini Rama Rao, Didier Rognan, Didier Lereclus
-
Patent number: 10851160Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: GrantFiled: March 21, 2017Date of Patent: December 1, 2020Assignees: Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Chu Strasbourg, les Hopitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 10828309Abstract: The present invention relates to the cosmetic or pharmaceutical use for a composition comprising a salicylic or nicotinic acid derivative inhibiting chemokines, for preventing or treating chronic internal and/or external inflammatory conditions.Type: GrantFiled: September 22, 2015Date of Patent: November 10, 2020Assignees: GREENPHARMA, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE STRASBOURGInventors: Philippe Bernard, Dayana Abboud, Jean-Luc Galzi, Nelly Frossard, Christelle Pillard, Quoc Tuan Do
-
Patent number: 10821159Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.Type: GrantFiled: January 29, 2015Date of Patent: November 3, 2020Assignees: UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, VAXINE PTY LTDInventors: Vincent Marion, Nikolai Petrovsky
-
Disintegratable core/shell silica particles for encapsulating and releasing bioactive macromolecules
Patent number: 10821082Abstract: The present invention relates to disintegratable core/shell silica particles encapsulating a bioactive macromolecule or bioactive macromolecule cluster in an active conformation, a method for producing the same, and uses thereof.Type: GrantFiled: June 12, 2015Date of Patent: November 3, 2020Assignee: UNIVERSITE DE STRASBOURGInventors: Luisa De Cola, Eko Adi Prasetyanto, Alessandro Bertucci, Dedy Septiadi